Neuronetics launches $30 million public stock offering to refinance debt

Neuronetics announced an underwritten public offering of 18,750,000 common shares at $1.60 each, with a 30‑day option for underwriters to buy up to an additional 2,812,500 shares. The company plans to use part of the net proceeds to repay a term loan and the remainder for general corporate purposes, while also amending its credit agreement to reduce revenue covenants if a $15 million prepayment is made by November 30, 2026. The stock fell 10% in after‑hours trading after the launch and dropped another 13% in extended trading after pricing.

The firm says the cash will help settle debt and mitigate the going‑concern warning noted in its recent Form 10‑Q filing; analysts note that the dilution and debt repayment could pressure the share price in the short term.

  • 1The offering comprises 18,750,000 shares priced at $1.60 per share.
  • 2Underwriters received a 30‑day right to purchase up to 2,812,500 additional shares at the same price.
  • 3Gross proceeds are expected to be about $30 million before underwriting discounts and other expenses.
  • 4The transaction is slated to finalize near November 12, 2026, pending standard closing requirements.
  • 5Amendment No. 6 to the credit facility requires a prepayment of at least $15 million by November 30, 2026 to reduce revenue covenants.
  • 6Shares dropped roughly 10% in after‑hours trading after the offering was announced.

Sources